Fluid biomarkers for disease activity in multiple sclerosis

Abstract

Get full access to this article

View all access options for this article.

References

Sellebjerg

Börnsen

Ammitzbøll

et al . Defining active progressive multiple sclerosis. Mult Scler 2017; 23(13): 127–135.

Novakova

Axelsson

Khademi

et al . Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. J Neurochem 2017; 141(2): 296–304.

Axelsson

Malmestrom

Gunnarsson

et al . Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler 2014; 20(1): 43–50.

Duits

Martinez-Lage

Paquet

et al . Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimers Dement 2016; 12(2): 154–163.

Engelborghs

Niemantsverdriet

Struyfs

et al . Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement 2017; 8: 111–126.

Teunissen

Malekzadeh

Leurs

et al . Body fluid biomarkers for multiple sclerosis–the long road to clinical application. Nat Rev Neurol 2015; 11(10): 585–596.

Gisslen

Price

Andreasson

et al . Plasma concentration of the Neurofilament Light Protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study. Ebiomedicine 2016; 3: 135–140.

Kuhle

Barro

Andreasson

et al . Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 2016; 54: 1655–1661.

Piehl

Kockum

Khademi

et al . Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Mult Scler. Epub ahead of print 1 June 2017. DOI: 10.1177/1352458517715132.

10.

Disanto

Barro

Benkert

et al . Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol 2017; 81(6): 857–870.